secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immix Biopharma, Inc. (IMMX)
CIK:        0001873835
Form:       8-K
Filed at:   2026-05-21T21:28:23+00:00
Accession:  0001493152-26-024872
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immix Biopharma prices $150M public offering of 16.8M shares at $8.94
---------------------------------------------------------------------

- Gross proceeds $150M; net proceeds ~$140.65M after discounts and expenses.
- Offering of 16,778,524 shares priced at $8.94 per share; closes May 22, 2026.
- Net proceeds to fund NXC-201 development, working capital, and general corporate purposes.
- Cash runway extended to mid-2028 with existing cash plus offering net proceeds.
- Morgan Stanley leads underwriters; BofA Securities, LifeSci Capital, Mizuho, Needham co-manage.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873835/000149315226024872/0001493152-26-024872-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873835/000149315226024872/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-024872

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer